Aigerim Zhakypbek

Ms. Aigerim Zhakypbek


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Ġylym ža̋ne bìlìm
Verified
Journal Article
Open access
PDF file
МСМадина Сейсенбаева
Мадина Сейсенбаева
AZAigerim Zhakypbek
Aigerim Zhakypbek
ZKZhumagali Khoshemetov
Zhumagali Khoshemetov
НОНургуль Оразымбетова
Нургуль Оразымбетова
В данной работе был исследован вакцинный СТИ-1, сибиреязвенная культура (матрикс № 71 вторая вакцины Ценковского) и эпизоотический штамм 78/НИИПББ на определение наилучшего метода получение антигена с оптимально высокой концентрацией и активностью, для приготовления диагностического набора. Осуществлен сравнительные анализы влияние температурно-временного режима на объем и активность антигена. Возбудители сибирской язвы были культивированы в питательных средах Хоттингера ФБУН ГНЦ ПМБ Россия и в бульоне Хоттингера ФБУН ГНЦ ПМБ Россия. Активность полученных антигенов определяли постановкой РНГА используя диагностикум эритроцитарный сибиреязвенный иммуноглобулинный, сухой, постановку РДП проводили на Bacto agar с риванолом, также измеряли концентрацию белка на Genway, Genova plus методом Лоури. Далее используя выбранную методику культивирования штаммов СТИ-1, Ценковского и 78/1 нами были приготовлены антигены 7-и разными способами. Установлены, что оптимальными условиями культивирования штаммов СТИ-1 и Ценковского является 48-72 часа для эпизоотического штамма 78/НИИПББ оптимальным временем культивирования является 36 часов, при 37 °С. Далее используя данный температурно-временной режим были приготовлены антигены 7-и разными способами. В результате наиболее активные антигены получены №1 способом, у которых активность в РДП составила 1:32, в РНГА - 1:1024. Также для полноты исследования был подобран стабилизатор для лиофилизации и хранение антигенов. Исходный активность антигена в РДП 1:32, а со стабилизатором после сушки составило 1:16, в РНГА исходный активность 1:2048, после сушки 1:512-1:1024.

7 August 2026 in Viruses
Verified
Journal Article
Open access
PDF file
AZAigerim Zhakypbek
Aigerim Zhakypbek
LKLespek Kutumbetov
Lespek Kutumbetov
KGKuzembekova Gulnur
Kuzembekova Gulnur
KSKamshat Shorayeva
Kamshat Shorayeva
NKNurlan Kozhabergenov
Nurlan Kozhabergenov
Kuandyk ZhugunissovKuandyk Zhugunissov
Kuandyk Zhugunissov
Orthopoxviruses are zoonotic DNA viruses of continuing public health importance, as highlighted by recent global mpox outbreaks. The high antigenic similarity among orthopoxviruses enables cross-reactive immune responses but complicates the development of serological diagnostic systems for serosurveillance, assessment of previous exposure, evaluation of vaccine-induced immunity, and species differentiation. This review summarizes current knowledge regarding the structure, biological functions, and diagnostic and vaccine potential of major orthopoxvirus recombinant antigens. Particular attention is given to the genomic organization of Orthopoxvirus, differences between intracellular mature virion (IMV) and extracellular enveloped virion (EV) forms, and the characteristics of key antigens, including A29, M1, H3, A35, and B6. Comparative phylogenetic analyses demonstrated a high degree of conservation among structurally important orthopoxvirus proteins while also identifying variable regions potentially relevant for differential diagnostics. Available evidence indicates that IMV-associated proteins are primarily involved in virus neutralization, whereas EV-associated antigens contribute mainly to limiting viral dissemination. Consequently, multicomponent antigen strategies combining IMV- and EV-associated proteins appear to provide the greatest potential for the development of effective serological assays and next-generation subunit vaccines. Overall, rational antigen selection should be based on integrated evaluation of structural, functional, and immunological properties to optimize orthopoxvirus diagnostic and vaccine platforms.

28 July 2026 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
GNGulnur Nakhanova
Gulnur Nakhanova
OCOlga Chervyakova
Olga Chervyakova
KSKamshat Shorayeva
Kamshat Shorayeva
AZAigerim Zhakypbek
Aigerim Zhakypbek
SMSabina Moldagulova
Sabina Moldagulova
Kuandyk ZhugunissovKuandyk Zhugunissov
Kuandyk Zhugunissov
Recombinant superoxide dismutase (SOD) protein is a promising antigen candidate for brucellosis vaccines, and its quantitative determination is essential for vaccine quality control, standardization, and regulatory compliance. Although enzyme-linked immunosorbent assay (ELISA) is widely used for antigen quantification, its application to vaccine formulations may be limited due to chemical modifications of antigenic determinants occurring during detoxification and adjuvantation processes. Therefore, alternative analytical methods, such as single radial immunodiffusion (SRID), which enable direct antigen quantification independent of antigenic determinant modifications, represent valuable tools for vaccine analysis. The aim of this study was to develop and validate a single radial immunodiffusion (SRID) assay for the quantitative determination of recombinant SOD protein and to obtain hyperimmune sera in sheep. Sheep were immunized with recombinant SOD protein formulated with aluminum hydroxide or AddaS03 adjuvants. Antibody responses were evaluated using agar gel immunodiffusion (AGID) and enzyme-linked immunosorbent assay (ELISA). Immunization with aluminum hydroxide induced higher antibody titers than AddaS03. By day 42, ELISA titers reached 1:25,600 in the aluminum hydroxide group compared with 1:3200 in the AddaS03 group. The obtained hyperimmune sera were used for SRID assay development. The optimized SRID assay demonstrated high reproducibility and specificity, with no cross-reactivity against unrelated proteins. A linear relationship was observed between the square of the precipitation ring diameter (D2) and antigen concentration (R2 = 0.956–0.989). The assay showed a limit of detection of 0.312 μg/mL, a linear range of 0.625–10 μg/mL, high precision (CV < 2%), and robustness under varying analytical conditions. The developed SRID assay represents a specific, reproducible, and robust tool for quantitative control of recombinant SOD protein in vaccine formulations.

30 October 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
BYBolat Yespembetov
Bolat Yespembetov
SASabira Alpysbayeva
Sabira Alpysbayeva
MSMakhpal Sarmykova
Makhpal Sarmykova
OCOlga Chervyakova
Olga Chervyakova
Kuandyk ZhugunissovKuandyk Zhugunissov
Kuandyk Zhugunissov
AAAkbope Abdykalyk
Akbope Abdykalyk
Background/Objectives: Brucellosis remains a widespread zoonosis, yet no licensed human vaccine exists and the live attenuated vaccines used in animals are unsuitable for people because of residual virulence and the risk of accidental infection. Recombinant platforms are attractive alternatives, but direct head-to-head comparisons within a single study are scarce. We compared the safety, immunogenicity and protective efficacy of three recombinant candidates: the AddaS03-adjuvanted subunit vaccine BruVac-Pro, the capripoxvirus-vectored BruVac-CPX and the influenza virus-vectored BruVac-FLU. Methods: Inbred BALB/c mice (n = 355) received a prime-boost immunization, except for the single-dose Rev-1 reference group. A subgroup of 10 animals per group was monitored serologically from day 0 and subsequently challenged intraperitoneally with virulent Brucella melitensis 16M, and the remaining animals were assigned to safety, vector-detection and cellular-immunity read-outs. The timing and prospective nature of allocation to the challenge cohort could not be documented; selection bias in the efficacy endpoint therefore cannot be excluded. Safety was assessed from clinical observation, body weight and early serum clinical chemistry; antigen-specific IgG to Omp16, Omp19, L7/L12 and SodC was measured by indirect ELISA; and protection was quantified from splenic bacterial load (Y), the protective index (PI) and the proportion of animals with no splenic recovery (n = 10 per group). Immunogenicity was assessed as humoral (IgG) responses only; antigen-specific cellular responses were measured in separate subsets of the same experiment and are reported separately. Results: Mortality during the immunization phase was confined to the three sublingually dosed viral-vector and stabilizer groups (CPX/CPX 4/50, CCFLU/CCFLU 3/55, FLU/FLU 1/55), with no deaths in the Pro/Pro, AddaS03/AddaS03, Rev-1 or PBS/PBS groups (8/160 versus 0/195); surviving animals showed no overt clinical signs. Influenza-vector RNA was not detected in serum or spleens at days 3 and 6 by a qualitative assay of undetermined sensitivity. Seroconversion to Omp16 and Omp19 was confined to the Pro-containing group; no animal in any group seroconverted to SodC, and responses to L7/L12 were confined to isolated single animals without a group-level pattern. Splenic burden differed across groups (Kruskal–Wallis, p = 4 × 10−7). BruVac-Pro gave the strongest protection (Y 2.32; PI 2.62; 70.0% with no recovery; p = 0.028 for splenic burden and adjusted p = 0.015 for the proportion of animals with no recovery, both versus the phosphate-buffered saline (PBS) control). BruVac-CPX showed only a non-significant trend towards reduced burden (PI 1.54; p = 0.57 after correction for multiple comparisons) without increasing clearance (20.0%), and BruVac-FLU did not prevent colonization. Rev-1 confirmed model validity (PI 3.15; 80.0%). Conclusions: Under the non-equivalent, formulation-specific regimens tested, BruVac-Pro was the only experimental formulation with no mortality and no overt clinical signs, produced the most consistent antigen-specific IgG response, and was the only experimental candidate to reduce day-14 splenic burden significantly relative to the PBS and adjuvant-only controls. These findings support further dose, mechanism and durability studies of this formulation, but do not establish platform superiority, sterile protection or suitability for human use.

30 September 2025 in Ġylym ža̋ne bìlìm
Verified
Journal Article
Open access
PDF file
NPNational Holding «QazBioPharm» ‘Research Institute of Biological Safety Problems
National Holding «QazBioPharm» ‘Research Institute of Biological Safety Problems
AZAigerim Zhakypbek
Aigerim Zhakypbek
OSO.N. Serikbayov
O.N. Serikbayov
ZKZhumagali Khoshemetov
Zhumagali Khoshemetov
NONurgul Orazymbetova
Nurgul Orazymbetova
Despite the global eradication of smallpox in 1977, the virus continues to pose a significant biosafety threat due to its potential use as a biological weapon. The smallpox virus is relatively easy to culture, can be preserved through lyophilization (freeze-drying), and remains stable when protected from high temperatures and ultraviolet radiation. These characteristics underscore the ongoing need for vigilant epidemiological surveillance, as well as the continued development of modern vaccines and reliable diagnostic tools.In this study, an attempt was made to obtain a human-specific antiserum suitable for the development of an enzyme-linked immunosorbent assay (ELISA) intended to evaluate the effectiveness of smallpox vaccines. Human γ-globulin, isolated by the Kohn alcohol fractionation method at a final concentration of 12.54 mg/mL, was used as the antigen. Laboratory animals—goats of local breeds and rabbits weighing 2–2.5 kg—were used to produce the antispecific serum. The immunization regimens varied in terms of the antigen doses administered, the intervals between injections, and the sites of administration.As a result of the experimental work, it was found that serum obtained from rabbits following immunization scheme No. 1 demonstrated the highest specific activity, with a titer of 1:64 in the diffusion precipitation reaction. This rabbit-derived antiserum will be used as the primary diagnostic reagent for optimizing ELISA conditions aimed at detecting antibodies to the Monkeypox virus.The development of highly specific and sensitive diagnostic methods, such as ELISA based on well-characterized antispecific sera, is critical for effective epidemiological monitoring. This is especially relevant in light of the re-emergence of orthopoxviruses like Monkeypox and the persistent threat of deliberate virus release. Continued advancements in diagnostic reagents will enhance public health preparedness and response strategies for orthopoxvirus-related diseases